Dasatinib
Sign in to save this workspacePrimary targets: BCR_ABL, ABL1, ABL2_ARG · FDA status: FDA Approved
Selectivity scorecard
KISS
87.97
Gini
0.699
CATDS
0.012
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Dasatinib. Strongest target: ABL2_ARG at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | ABL2_ARG | 100.0% | 0.0% |
| 2 | BLK | 100.0% | 0.0% |
| 3 | EPHA3 | 100.0% | 0.0% |
| 4 | EPHA5 | 100.0% | 0.0% |
| 5 | FYN | 100.0% | 0.0% |
| 6 | LCK | 100.0% | 0.0% |
| 7 | YES_YES1 | 100.0% | 0.0% |
| 8 | C_SRC | 100.0% | 0.0% |
| 9 | PEAK1 | 99.9% | 0.1% |
| 10 | HCK | 99.9% | 0.1% |
| 11 | DDR2 | 99.6% | 0.4% |
| 12 | LYN | 99.6% | 0.4% |
| 13 | FRK_PTK5 | 99.5% | 0.5% |
| 14 | EPHA2 | 99.4% | 0.6% |
| 15 | EPHB1 | 99.4% | 0.6% |
| 16 | DDR1 | 99.3% | 0.7% |
| 17 | BTK | 99.3% | 0.7% |
| 18 | EPHB4 | 99.3% | 0.7% |
| 19 | TXK | 99.1% | 0.9% |
| 20 | EPHA1 | 98.9% | 1.1% |
Selectivity landscape
Where Dasatinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Dasatinib.
Annotations
Sign in to read and post annotations.
Loading…